Entecavir of benefit in HBeAg-positive Hep B

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.542, 2007-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

By Veenstra David L.  

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 963-977

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

By Spackman D. Eldon   Veenstra David L.  

PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. : 937-949

Adis International

Access to resources Recommend Favorite

Entecavir outlasts the alernatives for affordable hep B therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 559, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Entecavir outlasts the alernatives for affordable hep B therapy

By  

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection

By Atay AE   Seven G   Yalcin K   Pasa S   Degertekin H  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1891-1896

Field House Publishing

Access to resources Recommend Favorite